KD Biopharma 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
3 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
EPAspire (eicosapentaenoic acid free fatty acid) / KD Biopharma, SLA Pharma
SLA Pharma_COVID: KD Pharma Group & SLA Pharma Initiate Clinical Trial For COVID-19

Recruiting
3
0
UK, US
EPAspire (eicosapentaenoic acid free fatty acid) - SLA Pharma, KD Biopharma
SLA Pharma, KD Biopharma
COVID-19
 
 
NCT04335032: EPA-FFA to Treat Hospitalised Patients With COVID-19 (SARS-CoV-2)

Recruiting
3
284
Europe
Eicosapentaenoic acid gastro-resistant capsules, Alfa, Placebo
S.L.A. Pharma AG
SARS-CoV-2
11/21
12/21
NCT03806426: Effect of EPA-FFA on Polypectomy in Familial Adenomatous Polyposis

Active, not recruiting
3
204
Europe
Eicosapentaenoic acid free fatty acid (EPA-FFA), ALFA, Placebo
S.L.A. Pharma AG
Familial Adenomatous Polyposis
06/24
07/24
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
EPAspire (eicosapentaenoic acid free fatty acid) / KD Biopharma, SLA Pharma
SLA Pharma_COVID: KD Pharma Group & SLA Pharma Initiate Clinical Trial For COVID-19

Recruiting
3
0
UK, US
EPAspire (eicosapentaenoic acid free fatty acid) - SLA Pharma, KD Biopharma
SLA Pharma, KD Biopharma
COVID-19
 
 
NCT04335032: EPA-FFA to Treat Hospitalised Patients With COVID-19 (SARS-CoV-2)

Recruiting
3
284
Europe
Eicosapentaenoic acid gastro-resistant capsules, Alfa, Placebo
S.L.A. Pharma AG
SARS-CoV-2
11/21
12/21
NCT03806426: Effect of EPA-FFA on Polypectomy in Familial Adenomatous Polyposis

Active, not recruiting
3
204
Europe
Eicosapentaenoic acid free fatty acid (EPA-FFA), ALFA, Placebo
S.L.A. Pharma AG
Familial Adenomatous Polyposis
06/24
07/24

Download Options